Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards.

Body composition Least significant change Muscle wasting Positron emission tomography-computed tomography (PET/CT) Precision test Squamous cell carcinoma of the head and neck

Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
05 2022
Historique:
received: 18 11 2021
revised: 02 03 2022
accepted: 05 03 2022
pubmed: 9 4 2022
medline: 3 5 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

Computed tomography images acquired during routine cancer care provide an opportunity to determine body composition with accuracy and precision. Quantification of skeletal muscle is of interest owing to its association with clinical outcomes. However, the standards of precision testing considered mandatory in other areas of radiology are lacking from the literature in this area. We aim to describe the change in skeletal muscle over time at different anatomical levels using the precision error. Thirty-eight male patients with squamous cell carcinoma of the head and neck were evaluated at two time points encompassing their treatment plan. Precision testing consisted of analyzing the cross-sectional area (CSA) of the skeletal muscle and total adipose tissue of 76 CT studies (38 images at baseline repeated twice and 38 follow-up images repeated twice) measured by a skilled observer. The % coefficient of variation (%CV), the root-mean-square standard deviation (RMS SD) and the corresponding 95% least significant change (LSC) were calculated for four anatomical levels: upper arm, thigh, chest and abdomen. The median time between scans was 223.6 (SD 31.2) days. Precision error (% CV) for total skeletal muscle cross sectional area was 0.86% for upper arm, 0.26% for thigh, 0.39% for chest and 0.63% for abdomen. The corresponding LSC values in upper arm, thigh, chest and abdomen were 2.4%, 0.7%, 1.1% and 1.8%, respectively. Based on the LSC for RMS SD, patients were classified in two categories according to muscle cross-sectional area: stable (i.e within LSC value) or gained and loss. To compare the four anatomical levels, the proportion of patients with muscle loss exceeding the LSC value was 74.3% for arm, 86.2% for thigh, 82.9% for chest and 76.3% for abdomen. For these same anatomic regions, the mean muscle loss for those patients classified below the LSC was 14.6% (SD 9.3), 13.4% (SD 7.8), 11.9% (SD 6.5) and 11.6% (SD 5.5), respectively. Only the loss of muscle area was significantly higher in thigh (p = 0.023), using L3 as the reference level. We recommend the uniform use of a standard precision test when reporting muscle change over time. LSC values vary from 0.7 to 2.4% depending on anatomic site; with the lowest precision error to detect change in the thigh. Based on this analysis, muscle wasting appears to be systemic and while present in limbs and trunk is significantly higher in the thigh than in the chest, abdomen or upper arm.

Sections du résumé

BACKGROUND
Computed tomography images acquired during routine cancer care provide an opportunity to determine body composition with accuracy and precision. Quantification of skeletal muscle is of interest owing to its association with clinical outcomes. However, the standards of precision testing considered mandatory in other areas of radiology are lacking from the literature in this area. We aim to describe the change in skeletal muscle over time at different anatomical levels using the precision error.
METHODS
Thirty-eight male patients with squamous cell carcinoma of the head and neck were evaluated at two time points encompassing their treatment plan. Precision testing consisted of analyzing the cross-sectional area (CSA) of the skeletal muscle and total adipose tissue of 76 CT studies (38 images at baseline repeated twice and 38 follow-up images repeated twice) measured by a skilled observer. The % coefficient of variation (%CV), the root-mean-square standard deviation (RMS SD) and the corresponding 95% least significant change (LSC) were calculated for four anatomical levels: upper arm, thigh, chest and abdomen.
RESULTS
The median time between scans was 223.6 (SD 31.2) days. Precision error (% CV) for total skeletal muscle cross sectional area was 0.86% for upper arm, 0.26% for thigh, 0.39% for chest and 0.63% for abdomen. The corresponding LSC values in upper arm, thigh, chest and abdomen were 2.4%, 0.7%, 1.1% and 1.8%, respectively. Based on the LSC for RMS SD, patients were classified in two categories according to muscle cross-sectional area: stable (i.e within LSC value) or gained and loss. To compare the four anatomical levels, the proportion of patients with muscle loss exceeding the LSC value was 74.3% for arm, 86.2% for thigh, 82.9% for chest and 76.3% for abdomen. For these same anatomic regions, the mean muscle loss for those patients classified below the LSC was 14.6% (SD 9.3), 13.4% (SD 7.8), 11.9% (SD 6.5) and 11.6% (SD 5.5), respectively. Only the loss of muscle area was significantly higher in thigh (p = 0.023), using L3 as the reference level.
CONCLUSIONS
We recommend the uniform use of a standard precision test when reporting muscle change over time. LSC values vary from 0.7 to 2.4% depending on anatomic site; with the lowest precision error to detect change in the thigh. Based on this analysis, muscle wasting appears to be systemic and while present in limbs and trunk is significantly higher in the thigh than in the chest, abdomen or upper arm.

Identifiants

pubmed: 35395556
pii: S0261-5614(22)00090-5
doi: 10.1016/j.clnu.2022.03.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1059-1065

Informations de copyright

Copyright © 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Lorena Arribas (L)

Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Head and Neck Cancer Unit, Bellvitge University Hospital- Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain; University of Barcelona, Barcelona, Spain. Electronic address: larribas@iconcologia.net.

Aida Sabaté-Llobera (A)

Department of Nuclear Medicine, PET Unit-IDI, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Mónica Cos Domingo (MC)

Department of Neuroradiology, IDI-Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain; Head and Neck Cancer Unit, Bellvitge University Hospital- Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.

Miren Taberna (M)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Head and Neck Cancer Unit, Bellvitge University Hospital- Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain; Medical Oncology Department, Catalan Institute of Oncology (ICO), ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Maria Sospedra (M)

Unitat de Nutrició Clínica I Dietética, Hospital Universitari Germans Trias I Pujol (HUGTIP), Badalona, Barcelona, Spain.

Lisa Martin (L)

Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Edmonton, Canada.

Ana Regina González-Tampán (AR)

Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain; Head and Neck Cancer Unit, Bellvitge University Hospital- Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.

Natalia Pallarés (N)

Unitat de Bioestadística (UBiDi). Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Ricard Mesía (R)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Head and Neck Cancer Unit, Bellvitge University Hospital- Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain; Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, B-ARGO Group, Barcelona, Spain.

Vickie E Baracos (VE)

Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Edmonton, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH